Herbalife International, Inc.

Herbalife International, Inc.

Herbalife International, Inc.

Overview
Date Founded

1980

Headquarters

1800 Century Park East,Century City, CA 90067

Type of Company

Private

Industries

Wholesale: Consumer Non-Durables/Sundries
Retail: Food & Beverage

Company Description

Herbalife International, Inc. manufactures and distributes personal health care products such as weight control mixes, nutritional supplements, shampoos, lotions, sunscreens, and body oils. It also provides weight management products to support weight loss and a healthy lifestyle. The company was founded in February1980 by Mark Reynolds Hughes and is headquartered in Los Angeles, CA.

Contact Data
Trying to get in touch with decision makers at Herbalife International, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Co-President & Chief Strategic Officer

Partner

Senior Director

Plant Controller

Coordinator

Sales Coordinator

Marketing Coordinator

Production Coordinator

Marketing Director

Board of Directors

Professor at The Ohio State University

President & Chief Executive Officer at Cadus Corp.

Former Chief Executive Officer at Juicero, Inc.

Chief Executive Officer & President at Global Net Lease, Inc.

Member, Board of Directors at Herbalife Nutrition Ltd.

President & Chief Executive Officer at GRC Advisory Services LLC

Managing Director at Icahn Enterprises LP

Executive Officer at Dai Geo US, Inc.

Managing Partner at Venetus Partners LP

Principal & Founding Partner at Hernández Ventures

Paths to Herbalife International, Inc.
Potential Connections via
Relationship Science
You
Herbalife International, Inc.
Recent Transactions
Details Hidden

J. H. Whitney & Co. LLC, Golden Gate Private Equity, Inc. purchase Herbalife International, Inc.

Transaction Advisors
Investment Advisor

Advised onJ. H. Whitney & Co. LLC, Golden Gate Private Equity, Inc. purchase Herbalife International, Inc.

Accountant

Advised onJ. H. Whitney & Co. LLC, Golden Gate Private Equity, Inc. purchase Herbalife International, Inc.

Legal Advisor

Advised onJ. H. Whitney & Co. LLC, Golden Gate Private Equity, Inc. purchase Herbalife International, Inc.

Advisors & Consultants
Legal Advisor

Former Partner at Bingham McCutchen LLP

Legal Advisor

Senior Vice President at The Glover Park Group, Inc.

Political Donations
$1,000
2014
$1,000
2014
$2,000
2013
Suppliers
Biocon Ltd. Medical Support Services | Bangalore, KA

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine